Loading...
Sexual dysfunction associated with the use of serotonin reuptake inhibitors (SRIs) has been reported in 30% to 70% of treated patients and is a significant contributor to discontinuation of these medications. In a multicenter, university-based, double-blind, prospective study that was funded by the manufacturer of sildenafil, 90 antidepressant-treated men with sexual dysfunction and remitted depression were randomized to receive 6 weeks of treatment with sildenafil (50 to 100 mg) or placebo (mean age, 45; duration of antidepressant use, 27 months). Sexual dysfunction was defined as erectile problems, delayed ejaculation, or lack of orgasm. Most patients were taking an SSRI.
On standardized rating scales, significantly more sildenafil recipie…